Pfizer CEO Albert Bourla is expected to attend a $25 million fundraiser at US President Donald Trump’s golf club in ...

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

JPMorgan U.S. Momentum Factor ETF has diversified momentum exposure, competitive returns, and low expenses. Read here for an ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

HYDERABAD — Dr Reddy’s Laboratories is gearing up to enter the booming global obesity drug market with a more affordable ...

He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug ...

Trump’s tariff regime has shaken global trade — and Ireland’s critical pharma sector is bracing for long-term change ...

President Donald Trump's new European tariffs could significantly increase the cost of Novo Nordisk's weight loss drug, Ozempic.

Health-care companies fell as traders continued to flee the health-insurance subsector. UnitedHealth Group's woes continued, with shares of the largest insurer by enrollees losing 5% to bring its ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

WARSAW — The Lilly Endowment Community Scholarship is now accepting applications until Sep15. This scholarship is a four-year ...